NCT02320227已完成不适用
A Single-Center, Clinical Study to Evaluate the Safety of a Non-Fragranced Personal Lubricant in Healthy Female Subjects
Church & Dwight Company, Inc.2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2014年12月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- Number of Participants With Observed Local Edema
研究概览
简要总结
To evaluate the safety of a personal lubricant when used as indicated as a personal lubricant in the vagina and vulvar/perineal areas at least four times weekly for two weeks in a population of healthy females
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Subject is female between the ages of 18 and 49 years (at lease 21 subjects) or 50-60 years (no more than 9 subjects);
- •Subject is using adequate non-barrier method of birth control [established us of hormonal methods of contraception (oral, injected, implanted, or patch), intrauterine device (IUD) or intrauterine system (IUS), surgical sterilization (e.g. in a monogamous relationship with male partner with vasectomy];
- •Subject is free of any vaginal disorders;
- •Subject is sexually active and in a monogamous, heterosexual relationship, and whose male partner is willing and able to give informed consent and agrees to engage in sexual intercourse at least twice each week during the two-week study (at least 50% and up to 100% of the study population) or is not sexually active (no more than 50% of the population);
- •Subject is a personal lubricant user and agrees to replace her usual personal lubricant with the investigational product;
- •Subject has normal menstrual cycle and is not expected to menstruate 2-4 days before or after the examination days;
- •Subject agrees to use the provided investigational product at least four times weekly (including at least twice weekly during sexual intercourse for subjects with monogamous, male partners) over the two-week study period;
- •Subject exhibits no clinically significant evidence of vulvar or vaginal irritation, as determined by a study doctor, and no reports of sensory irritation at the baseline examination;
- •Subject is willing to refrain from introducing any new vaginal products, or using vaginal medication or local contraceptives (including condoms and hormonal rings), during the course of this study;
- •Subject agrees to refrain from douching or using any medications, powder, lotions or personal care products in the vulvar or perianal area for the duration of the study (Note: subjects may continue to use their usual pantyliner, if any);
- •Subject is willing to use a urine pregnancy test provided to them at baseline and on the third visit (Week 2, day 14);
- •Subject has a standard Clinical Research Laboratories, Inc. (CRL) Medical History form on file at CRL and has completed study specific Medical History and Screener/Inclusion forms;
- •Subject has signed and, if sexually active and in a monogamous relationship, whose partner has signed, an Informed Consent Form (ICF) in compliance with 21 CFR Part 50: "Protection of Human Subjects";
- •Subject (and male partner, if applicable) has completed a HIPAA Authorization Form in conformance with 45 CFR Parts 160 and 164;
- •Subject is dependable and able to follow directions as outlined in the protocol;
- •Subject receives a score of 0 or 0.5 for erythema and edema, and 0 for sensorial irritation (burning, stinging, itching, and dryness) during the first examination.
排除标准
- •Subject is pregnant, nursing, or planning a pregnancy;
- •Subject is post-menopausal or has had a hysterectomy;
- •Subject is currently using, or has used within two weeks prior to study initiation, any systemic or topical corticosteroids, vasoconstrictors, antibiotics, anti-inflammatories, or antihistamines;
- •Subject has known allergies to vaginal or any cosmetic products (including lotions, moisturizer, powder, sprays, etc.);
- •Subject reports a history of recurrent bladder, vaginal infection, or incontinence;
- •Subject exhibits or reports gynecological abnormalities or has had vaginitis within 60 days prior to study initiation.
- •Subject is expected to menstruate 2-4 days before or after the time of the first, second, and third examination;
- •Subject uses a vaginal ring, diaphragm or cervical/vault caps, condoms, or condoms with spermicide as a means of contraception;
- •Subject has participated in a study involving the vaginal area or in an investigational systemic drug study within two weeks of study initiation;
- •Subject receives a score higher than 0.5 for erythema, edema, or >0 for burning, stinging, or itching, during the first examination or shows any other sign of mucosal irregularities (dryness, papules, vesticulation, fissure).
结局指标
主要结局
Number of Participants With Observed Local Edema
时间窗: 14 days
Number of participants with observed edema by OB/GYN examination.
Number of Participants With Observed Local Erythema
时间窗: 14 Days
Number of participants with observed local erythema by OB/GYN examination.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
A Single-Center, Clinical Study to Evaluate the Safety of a Fragranced Personal Lubricant in Healthy Female SubjectsErythemaEdemaNCT02320214Church & Dwight Company, Inc.30
已完成
不适用
Safety Study of a Sensitive Sensual Touch and Personal LubricantInadequate LubricationNCT01271036Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.124
已完成
不适用
A Single-Center, Clinical Study to Evaluate the Safety of a New Personal Lubricant in Healthy Female SubjectsErythemaEdemaNCT02737852Church & Dwight Company, Inc.32
已完成
不适用
Safety Study for an All-in-One Body and Personal LubricantLubricating AgentsNCT01189617Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.70
已完成
不适用
A Safety Evaluation of Personal Lubricant Product When Used by Couples in Home-use ConditionsCoitusNCT00779025Johnson & Johnson Consumer and Personal Products Worldwide82